Comparative Pharmacology
Head-to-head clinical analysis: FLUORODOPA F18 versus ULTRATAG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUORODOPA F18 versus ULTRATAG.
FLUORODOPA F18 vs ULTRATAG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorodopa F18 is a radioactive diagnostic agent that is taken up by dopaminergic neurons in the striatum and converted by aromatic L-amino acid decarboxylase to fluorodopamine, which is stored in presynaptic vesicles. The emitted positrons allow for PET imaging to assess functional integrity of the nigrostriatal dopaminergic system.
Inhibits hepatic glucose production by activating AMP-activated protein kinase (AMPK) and reduces intestinal glucose absorption; also improves insulin sensitivity.
185-370 MBq (5-10 mCi) intravenous bolus injection for positron emission tomography imaging. Administered once per imaging session.
NOT FOUND
None Documented
None Documented
110 minutes (physical half-life of F-18); biological half-life is approximately 2-3 hours, allowing imaging up to 4-6 hours post-injection.
Terminal elimination half-life is 12-15 hours (mean 13.5 h); clinically significant for twice-daily dosing in hepatic impairment or drug interactions.
Primarily renal excretion; approximately 70-80% of the injected dose is excreted unchanged in urine within 2 hours, with the remainder eliminated via biliary/fecal routes (<5%).
Primarily renal excretion of unchanged drug (60-70%); biliary excretion accounts for 20-25%; fecal elimination <10%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical